Sidley Represents MacroGenics in the Sale of Its GMP Manufacturing Operations

Sidley is representing MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing antibody-based cancer therapeutics, in its US$122.5 million sale of its good manufacturing practice drug substance operations to Bora Pharmaceuticals Co., Ltd., a global pharmaceutical manufacturer and distributor headquartered in Taiwan. Bora will acquire MacroGenics’ manufacturing site, CDMO operations, and associated personnel, providing MacroGenics with additional non-dilutive capital to support advancement of its antibody-based therapeutic candidates.

The Sidley team is being led by Aaron Rigby and Rachel Fridhandler (M&A and Private Equity) and Joshua Hofheimer (Technology and Life Sciences Transactions), and includes Jonathan Litsey and Kelly Ball (M&A and Private Equity); Sabrina Glavota and Karena Kong (Technology and Life Sciences Transactions); Mark Langdon and Donielle McCutcheon (Healthcare); Deeona Gaskin and Julea Lipiz (Food, Drug and Medical Device); Tara Lancaster and Patrick Gray (Tax); Eric Winwood (Employee Benefits and Executive Compensation); and Jim Ducayet (Securities and Shareholder Litigation).